Open Orphan Plc (GB:HVO) has released an update.
hVIVO plc, a leading contract research organisation, has secured its largest field study contract for a Phase 2b trial of an influenza drug candidate, planning to enrol up to 1,000 volunteers. The study will leverage hVIVO’s expanded outpatient facilities and its volunteer recruitment platform, FluCamp, expecting to drive revenue growth and improve resource utilization in FY 2025. CEO Yamin ‘Mo’ Khan highlights the contract as evidence of hVIVO’s effective recruitment and a significant step in the company’s growth strategy.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
